Search results

Dr Anne Hellstedt has been appointed Director of ANSTO’s Innovation Precinct.

Both the Australian Centre for Neutron Scattering  and the National Deuteration Facility share in grants

The new targeted treatment for aggressive prostate cancer, which include lutetium produced at ANSTO, has shown to produce more potent and durable responses in men and with fewer side-effects.

Three new federal grants were announced to support manufacturing and nuclear technologies.

ANSTO's Melbourne location is home to the ANSTO-owned and operated Australian Synchrotron. The Synchrotron is one of the Australia's most significant pieces of scientific infrastructure.

An ANSTO radiochemist has been awarded a scholarship to carry out research at the world-renowned Sloan Kettering Cancer Center in New York.

With over 70 years of nuclear expertise, ANSTO offers expert education and training programs

Australian clean energy technology company, entX Limited is taking advantage of ANSTO’s unique capacity to generate tailored radioisotope products in the OPAL multi-purpose nuclear reactor to advance a series of innovative projects.

Tool developed for producing F-18 radiopharmaceuticals for PET imaging.

A large team of international researchers have used synchrotron techniques to understand how key proteins contribute to the virulence of the rabies virus, sometimes called the “zombie virus.”

Research to identify past human interactions with the environment and clarify information which may result from human impact or responses to changing environments.